SCHEMBL2256240

SCHEMBL2256240

Cc1cc(NC(=O)Nc2cccc(CN3CCN(S(=O)(=O)C4CC4)C[C@@H]3C)c2F)ccn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 5/20 0.36
PIK3R1 P27986 3/20 0.36
SMARCA2 P51531 1/20 0.36
SMARCA4 P51532 1/20 0.36
CCR3 P51677 5/20 0.36
ROCK2 O75116 1/20 0.35
LIMK1 P53667 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35
MAPK10 P53779 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
MAPT P10636 1/20 0.34
AURKA O14965 1/20 0.34
AURKB Q96GD4 1/20 0.34
PIK3CA P42336 1/20 0.33
PIK3CG P48736 1/20 0.33
PTGER3 P43115 1/20 0.33
RORC P51449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2252817 0.92 MTOR (0.38) MTORPIK3R1SMARCA2SMARCA4CCR3
SCHEMBL2252503 0.90 MTOR (0.36) MTORPIK3R1SMARCA2SMARCA4CCR3
SCHEMBL2252506 0.89 PIK3R1 (0.37) MTORPIK3R1SMARCA2SMARCA4CCR3
SCHEMBL3204743 0.88 CCR3 (0.43) SMARCA2SMARCA4CCR3RORCDHODH
SCHEMBL2254757 0.86 SMARCA2 (0.39) MTORPIK3R1SMARCA2SMARCA4CCR3
SCHEMBL5016676 0.85 SMARCA2 (0.39) MTORPIK3R1SMARCA2SMARCA4CCR3
SCHEMBL5016707 0.85 SMARCA2 (0.39) MTORPIK3R1SMARCA2SMARCA4CCR3
SCHEMBL5088756 0.83 MTOR (0.36) MTORPIK3R1SMARCA2SMARCA4CCR3
SCHEMBL2254750 0.83 SMARCA2 (0.37) MTORPIK3R1SMARCA2SMARCA4CCR3
SCHEMBL2254860 0.83 SMARCA2 (0.39) MTORPIK3R1SMARCA2SMARCA4CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989455-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2011-08-02 US claimed
EP-1962852-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP claimed
US-20070197497-A1 Compounds, compositions and methods CYTOKINETICS, INC. 2007-08-23 US claimed
WO-2007078839-A2 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2007-07-12 WO claimed
EP-1962852-B1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS INC (US) 2017-01-25 EP disclosed
US-7989455-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2011-08-02 US disclosed
EP-1962852-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP disclosed
US-20070197497-A1 Compounds, compositions and methods CYTOKINETICS, INC. 2007-08-23 US disclosed
WO-2007078839-A2 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197497-A1 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MTOR 1170/4885PIK3R1 3774/4885SMARCA2 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.